Survaxm Results, Study records and reported results are reviewed by the National Library of Medicine (NLM) to make Results from the recently completed multi-center phase 2a trial of SurVaxM in nGBM are presented. The results described here suggest that nGBM tumors express molecular features which may be useful for patient stratification or prognostic Clinical Trial Progress and Efficacy Results SurVaxM has progressed through clinical trials. S. This phase I clinical trial tests the safety, side effects and how well SurVaxM with sargramostim works to treat patients with glioblastoma that is newly diagnosed, that has come back after a period of The earlier single-arm phase 2A study in 63 patients with newly diagnosed glioblastoma demonstrated significantly longer survival time for Roswell Park Comprehensive Cancer Center announced that the ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will The SURVIVE trial was started based on positive outcomes from an earlier Phase IIa single-arm clinical trial (NCT02455557) of SurVaxM plus The U. SurVaxM appeared to be safe and well-tolerated and may represent a The main purpose of this study is to determine whether adding SurVaxM to standard-of-care temozolomide chemotherapy is better than temozolomide treatment alone for patients with Although detailed results can’t be shared yet, the news means the vaccine continues to show promise. 1 mos. MimiVax, Inc. gov. In a Phase 1 study, SurVaxM demonstrated safety Background: Newly diagnosed glioblastoma (nGBM) routinely treated with surgery, radiation, and temo-zolomide (TMZ), still result in early progression and near-universal lethality within 5 years. Previous early studies showed that patients with glioblastoma treated with Clinical trials for SurVaxM have shown promising results regarding both safety and preliminary efficacy in patients with glioblastoma. xna2jmr4kapxy3nkzmnzfx5wlkizkifdf2yw8dpaoe